GHRH vs GHRP: Only One of These Peptides Is GH-Selective

The growth hormone axis (GH axis) is among the better-studied endocrine systems. Recombinant growth hormone (HGH) was a central approach in clinical research for decades, but it carries drawbacks: supraphysiological, non-pulsatile GH levels, high costs and a side-effect profile that can become relevant with prolonged use.

The physiological regulation of the GH axis has been well established for decades. Both GH deficiency and GH excess are associated with clinically relevant disorders. This explains why controlled forms of GH stimulation and GH substitution are treated separately in research and clinical practice.

GH secretagogues are particularly relevant in this context because they stimulate the body's own release of growth hormone rather than supplying GH directly. The individual substances differ considerably in receptor profile, half-life, regulatory status and evidence base.

This is where GH secretagogues come in: peptides that prompt the body to release its own growth hormone instead of supplying it from outside. They can be divided into two main classes:

• GHRH analogues (Growth Hormone Releasing Hormone): mimic the hypothalamic releasing hormone
• GHRP (Growth Hormone Releasing Peptides): act via the ghrelin receptor (GHS-R1a)

This article compares frequently discussed representatives of both classes - Sermorelin, Tesamorelin, CJC-1295 and Ipamorelin - and explains why combinations of GHRH and GHRP signals have been studied in research.

We stock the peptides discussed in this article as research material with a per-batch certificate of analysis:

Sermorelingrowth

GHRH(1-29) analog for physiological growth hormone stimulation research

Tesamorelingrowth

Modified GHRH analog for lipodystrophy and metabolic liver research

CJC-1295 (No DAC)growth

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.

Ipamorelingrowth

Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.

CJC-1295 (No-DAC)/Ipamorelingrowth

2-in-1 growth hormone stack: CJC-1295 no-DAC (Modified GRF 1-29) + Ipamorelin, available as a 10 mg blend vial (5 mg + 5 mg co-lyophilized) or as the 20 mg option with two separately sealed single vials (10 mg + 10 mg). The CJC-1295 component is the short-acting no-DAC variant (about 30 minute half-life), not the long-acting DAC form. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses.

GH-Axis Researchgrowth

GHRH analogues and ghrelin-receptor agonists

GHRH Peptides: Mimicking the Natural Release Signal

GHRH (Growth Hormone Releasing Hormone) is a 44-amino-acid peptide hormone produced in the hypothalamus. It binds to the GHRH receptor (GHRH-R) on somatotropic cells of the pituitary and triggers the synthesis and secretion of growth hormone.

GHRH analogues imitate this natural signalling pathway. The result is a pulsatile GH release that more closely resembles the physiological pattern than exogenous HGH.

Sermorelin: GHRH(1-29)

Sermorelin is the shortest biologically active fragment of natural GHRH. It consists of the first 29 amino acids and retains the essential receptor-binding activity of the native 44-amino-acid peptide.

Properties at a glance:

• Structure: GHRH(1-29)NH2
• Half-life: approximately 10-20 minutes
• Mechanism: Direct activation of the GHRH receptor
• GH release: Pulsatile, physiological
• Negative feedback: Remains intact; somatostatin can continue to regulate GH secretion

Sermorelin was historically approved as a drug in the United States but was later discontinued and has been on the FDA list of discontinued drug products since 2008. For research purposes it remains relevant because it preserves the natural feedback loop of the GH axis, which conceptually distinguishes it from direct HGH administration.

Sermorelingrowth

GHRH(1-29) analog for physiological growth hormone stimulation research

Tesamorelin: GHRH with Improved Stability

Tesamorelin is a modified GHRH analogue in which a trans-3-hexenoic acid group has been attached to the tyrosine residue at position 1. This modification improves stability compared to native GHRH.

Key features:

• FDA approval since 2010 for the reduction of excess visceral fat in HIV-associated lipodystrophy
• Clinical studies showed a significant reduction in visceral adipose tissue, typically in the range of approximately 15 to 20% in published studies
• Further studies have examined effects on metabolic parameters and liver fat
• Preserves the GHRH-based mechanism of pulsatile GH release

Tesamorelin occupies a special position in this comparison because it is not only a research peptide but also a clinically approved drug with randomised, placebo-controlled data on visceral adipose tissue.

Tesamorelingrowth

Modified GHRH analog for lipodystrophy and metabolic liver research

CJC-1295 (No-DAC): Short-Acting GHRH Analogue

CJC-1295 is a synthetic GHRH analogue with 30 amino acids. In the research context, a distinction is usually made between a DAC variant and shorter-acting modified GHRH analogues:

• CJC-1295 with DAC (Drug Affinity Complex): Binds covalently to albumin in the blood, extending the half-life to 6-8 days
• CJC-1295 without DAC / Mod GRF 1-29: These designations are often equated in the market but should not be used as fully synonymous chemically. They refer to shorter-acting GHRH analogues with several amino acid substitutions for increased stability, with half-lives in the range of approximately 30 minutes

The DAC variant leads to considerably longer exposure, while shorter-acting variants are more commonly discussed for pulsatile protocols. Which form is preferred depends on the respective research design.

GHRP Peptides: The Ghrelin Pathway

Growth Hormone Releasing Peptides act via a different mechanism than GHRH analogues. They bind to the ghrelin receptor (GHS-R1a) - the same receptor activated by ghrelin. This receptor is located both in the pituitary and in the hypothalamus.

Compared to GHRH, it is particularly important that GHRPs can act synergistically. They amplify the GHRH signal and can release GH even when GHRH tone is low.

Ipamorelin: A Selective GHRP

Ipamorelin is considered a selective representative of the Growth Hormone Releasing Peptides. It is a pentapeptide (5 amino acids) that binds to GHS-R1a.

What distinguishes Ipamorelin from other GHRPs:

• In conscious swine, Ipamorelin released GH about as strongly as GHRP-6 but did not raise ACTH or cortisol, even at doses more than 200-fold above those needed for GH release (PMID 9849822)
• Prolactin, FSH, LH and TSH were unaffected by any of the secretagogues tested in that same work
• These selectivity data come from cell culture, rat and swine, not from a human trial
• Prolactin increases were also less pronounced in these studies than with older GHRPs
• Dose-dependent GH release was described
• Appetite stimulation is considered lower compared to GHRP-6

In the literature, Ipamorelin is therefore frequently described as a comparatively selective GHS-R1a agonist.

Ipamorelingrowth

Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.

GHRP-6 and GHRP-2: The Older Representatives

GHRP-6 was one of the first synthetic GH secretagogues. It produces a marked GH release, but with a broader activity profile:

• GHRP-6: Marked appetite stimulation through GHS-R1a activation, plus increases in cortisol and prolactin observed in studies
• GHRP-2: Potent GH release, but also described with cortisol and prolactin increases

Both peptides remain relevant for mechanistic comparisons, but clearly differ from Ipamorelin in their secondary hormone profile.

A study published in 2026 and available via PMC examined secondary structure, thermal stability and membrane interactions of GH-releasing peptides. The results suggest that membrane interactions may contribute to the biological activity of GHRPs. This is particularly relevant for formulation and model systems.

The Synergy: Why GHRH + GHRP Work Stronger Together

A consistent finding in secretagogue research is that GHRH and GHRP can act synergistically, not merely additively. This means that combined GH release can exceed the individual effect of either component.

The reason lies in the different signalling pathways:

1. GHRH activates GHRH-R - cAMP-dependent signalling pathway - GH synthesis and release
2. GHRP/Ipamorelin activates GHS-R1a - IP3/PKC signalling pathway - enhanced GH release + suppression of somatostatin

By simultaneously activating both pathways, the somatotropic cell is stimulated via multiple signalling cascades, while the inhibitory signal somatostatin can be attenuated at the same time.

CJC-1295 (No-DAC)/Ipamorelingrowth

2-in-1 growth hormone stack: CJC-1295 no-DAC (Modified GRF 1-29) + Ipamorelin, available as a 10 mg blend vial (5 mg + 5 mg co-lyophilized) or as the 20 mg option with two separately sealed single vials (10 mg + 10 mg). The CJC-1295 component is the short-acting no-DAC variant (about 30 minute half-life), not the long-acting DAC form. Stimulates natural GH release through two different pathways for amplified, more physiological growth hormone pulses.

Direct Comparison: GHRH vs GHRP at a Glance

Where Does IGF-LR3 Fit In?

All peptides discussed so far act upstream - they stimulate GH release from the pituitary. The released GH then acts on the liver and other tissues, where it stimulates the production of IGF-1 (Insulin-like Growth Factor 1). IGF-1 mediates a large part of the anabolic and regenerative effects of growth hormone.

IGF-1 LR3 (Long R3 IGF-1) is a modified IGF-1 analogue with:

• Substitution of glutamic acid at position 3 with arginine (R3 substitution)
• N-terminal extension of 13 amino acids
• Markedly reduced binding to IGF-binding proteins (IGFBPs), which increases bioavailability
• Regarding half-life, values in the range of 20 to 30 hours are frequently cited for IGF-1 LR3; however, robust human PK data on this are limited. For comparison, the terminal half-life of recombinant human IGF-1 in human studies is on the order of approximately 20 hours.

IGF-LR3 bypasses the entire GH axis and acts directly at the IGF-1 receptor. This makes it a fundamentally different research tool: it does not ask whether the pituitary is functioning but directly examines the downstream effects of the GH/IGF-1 axis.

Where the selectivity claim actually comes from

"Ipamorelin is selective" gets repeated across the web almost always without a citation. It traces back to one paper, and that paper rewards a close read.

Raun et al., European Journal of Endocrinology 1998 (PMID 9849822). The development paper for Ipamorelin, written by the GH Biology department at Novo Nordisk. Ipamorelin released GH about as strongly as GHRP-6 (in vitro EC50 1.3 vs 2.2 nmol/l; in conscious swine ED50 2.3 vs 3.9 nmol/kg). The decisive finding is the second one: GHRP-6 and GHRP-2 raised ACTH and cortisol, Ipamorelin did not, even at doses more than 200-fold above those needed for GH release. The authors therefore call Ipamorelin the first GHRP-receptor agonist with GH selectivity comparable to GHRH.

Arvat et al., Peptides 1997 (PMID 9285939). The human side, though for GHRP-2 and Hexarelin, described there as super-analogues of GHRP-6. Six young adults (22 to 27 years) and six elderly subjects (66 to 73 years) received 1 and 2 µg/kg intravenously. The result: neither is fully specific. Both raise prolactin, ACTH and cortisol, and their ACTH and cortisol releasing activity is comparable to that of hCRH, the hormone that actually drives that axis. This particular work does not contain the equivalent direct human measurement for GHRP-6 itself.

Cabrales et al., European Journal of Pharmaceutical Sciences 2013 (PMID 23099431). Pharmacokinetics of GHRP-6 in nine healthy men, single intravenous dose at three levels. Distribution half-life 7.6 minutes, elimination half-life 2.5 hours. Four of the nine subjects showed atypical concentration spikes during the elimination phase.

Svensson et al., 2000 (PMID 10828840). The only direct head-to-head of Ipamorelin and GHRP-6, in female Sprague-Dawley rats over twelve weeks. Both raised bone mineral content versus control. The honest part of the result: corrected for the body weight that also increased, the effect disappeared.

Frequently Asked Questions

The substances described here have different regulatory status depending on the active ingredient. This article is for informational purposes only and does not replace medical advice. It is not to be understood as a recommendation for use in humans.